Expert Interviews

Bryant England, MD: Multimorbidity in Patients With Rheumatoid Arthritis

August 17, 2021

Bryant England, MD, discusses his presentation entitled, “Epidemiology of Multimorbidity in Rheumatoid Arthritis."

John Cush, MD: Rheumatoid Arthritis Year in Review

August 12, 2021

John Cush, MD, discusses his upcoming lecture entitled, “Rheumatoid Arthritis: Year in Review,” which will be presented at the Congress of Clinical Rheumatology.

Randall Cron, MD, PhD: The Role of Rheumatologists in COVID-19

August 12, 2021

Randall Cron, MD, PhD, discuss his lectures entitled, “The Immunology of COVID” and “The Role of Rheumatologists in COVID-19,” which will be presented at the Congress of Clinical Rheumatology.

Brian LaMoreaux, MD, MS: Improving Outcomes for Patients With Gout

August 11, 2021

Brian LaMoreaux, MD, MS, discusses the recent study entitled, "Improving outcomes for patients hospitalised with gout: a systematic review."

Alexis Ogdie-Beatty, MD: UPLIFT Survey for Psoriatic Arthritis

August 11, 2021

Alexis Ogdie-Beatty, MD, discusses the UPLIFT survey and UPLIFT Innovation Challenge, the unmet needs of patients with psoriatic arthritis, and the clinical significance of the survey’s results.

Leonard Calabrese, DO: Autoimmune Diseases and COVID-19 as Immunology

August 10, 2021

Leonard Calabrese, DO, discusses his findings entitled, “Applied Immunology to Autoimmune Diseases: COVID-19 as Immunology,” which was presented at the Rheumatology Nurses Society Conference.

Richard Furie, MD: FDA Approval of Anifrolumab-Fnia for Systemic Lupus

August 04, 2021

Richard Furie, MD, discusses the recent FDA approval of anifrolumab-fnia for the treatment of patients with systemic lupus.

Philip J Mease, MD: Efficacy of Guselkumab for Reducing Fatigue in Psoriatic Arthritis

August 04, 2021

Philip J Mease, MD, discusses his study, “Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.”

Roy Fleischmann, MD: Safety of JAK Inhibitors

July 27, 2021

Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.

Richard Furie, MD: Safety and Efficacy of BIIB059 for Systemic Lupus Erythematosus

July 09, 2021

Richard Furie, MD, explains the safety and efficacy of BIIB059 for patients with systemic lupus erythematosus (SLE), the study design and background on his upcoming SLE study, and Biogen’s ongoing commitment to including underrepresented groups in its clinical trials.